Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Synonyms
(R)-indan-1-yl-prop-2-ynyl-amine
RAS
(1R)-N-propargylindan-1-amine
Rasagiline tartrate
(R)-N-2-Propynyl-1-indanamine
Rasagiline mesylate
Rasagilina
Rasagiline
Brand Names
Mint-rasagiline
Rasagiline Mylan
Rasagiline Ratiopharm
Teva-rasagiline
Rasagiline mesylate
Azilect
Rasagiline Mesylate
Jamp Rasagiline
Ag-rasagiline
Asn-rasagiline
Rasagiline
Apo-rasagiline
Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Categories
Agents that produce hypertension
Agents that reduce seizure threshold
Anti-Parkinson Drugs
Antidepressive Agents
Central Nervous System Agents
Central Nervous System Depressants
Compounds used in a research, industrial, or household setting
Cytochrome P-450 CYP1A2 Substrates
Cytochrome P-450 Substrates
Dopamine Agents
Drugs that are Mainly Renally Excreted
Enzyme Inhibitors
Hypotensive Agents
Indenes
Monoamine Oxidase B Inhibitors
Monoamine Oxidase Inhibitors
Nervous System
Neuroprotective Agents
Protective Agents
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
